GS967: Cardiac Late Sodium Current Inhibitor for Aging and Arrhythmia Research

Principle Overview: Targeting Late Sodium Current in Cardiac Dysfunction

Cardiac arrhythmias and diastolic dysfunction, especially prevalent in aging populations, are frequently linked to pathological increases in the late sodium current (late INa) in ventricular myocytes. The late sodium current emerges when cardiac sodium channels fail to properly inactivate, leading to sustained Na⁺ influx during the action potential plateau. This aberrant current is implicated in prolonged repolarization, Ca²⁺ overload, and heightened arrhythmogenic risk in conditions ranging from heart failure to ischemia and congenital long QT3 syndromes (recent mechanistic study).

GS967 (SKU: B5850) is a potent, selective, and novel inhibitor of this late sodium current, exhibiting an IC₅₀ of 0.13 μM in ventricular myocytes and 0.21 μM in isolated heart preparations. By offering minimal use-dependence and sparing peak sodium current under physiological conditions, GS967 enables researchers to dissect the exact role of late INa in cardiac pathophysiology — a major advance for both experimental reproducibility and translational potential (advanced inhibitor guide).

Step-by-Step Workflow: Integrating GS967 into In Vitro Cardiac Electrophysiology

GS967's selective action empowers in vitro and ex vivo models to isolate the contribution of late sodium current to arrhythmogenic processes, especially in aged or genetically altered myocardium.

Protocol Parameters

• Stock preparation: Dissolve GS967 in DMSO at ≥13.35 mg/mL (38.4 mM), or in ethanol at ≥25.52 mg/mL (73.5 mM) using ultrasonic agitation if needed. Avoid water due to insolubility.
• Working concentration: For isolated ventricular myocyte patch-clamp assays, apply 0.1–0.5 μM GS967—aligning with the reported IC₅₀ of 0.13 μM for late INa inhibition (product information).
• Temperature and solution handling: Conduct perfusion studies at 35–37°C; prepare fresh GS967 working solutions immediately before use and discard unused solutions to avoid degradation, as long-term storage is not recommended (product page).

For in vitro cardiac electrophysiology setups, GS967 can be superfused over Langendorff-perfused hearts or added to bath solutions in multi-well platforms for high-throughput assays. In patch-clamp workflows, pre-equilibrate cells with GS967 for 10–15 minutes before late INa measurements to ensure steady-state block. Always include a DMSO-only control at the corresponding solvent concentration (≤0.1% v/v is standard).

Key Innovation from the Reference Study

The reference study introduces a paradigm shift by pinpointing phosphorylation of the cardiac sodium channel Nav1.5 at Ser571 as a central driver of increased late sodium current with aging. Using both wild-type and genetically engineered mice, the authors demonstrated that:

• Late INa rises by approximately 60% in aged (26–30 month) mice versus young (3 month) animals.
• Action potential duration at 90% repolarization (APD90) is prolonged by ~50% in aged cardiomyocytes.
• Phosphomimetic Nav1.5 mutations (mimicking persistent phosphorylation) induce premature diastolic dysfunction and delayed repolarization, while phosphoablated mutations (blocking phosphorylation) largely prevent these age-related defects.

Critically, late INa inhibition reversed both delayed repolarization and impaired diastolic filling, providing direct evidence that pharmacological blockade of late sodium current can restore electrical and mechanical function in the aging heart. For experimental design, this means that selective inhibitors like GS967 are essential for dissecting the mechanistic role of late INa in age-related cardiac disease and for validating therapeutic strategies (study link).

For practical assay choices, supplementing standard field potential or APD measurements with GS967 application allows unambiguous attribution of observed aging phenotypes to late sodium current activity. This is especially powerful when working with aging models, Nav1.5 mutants, or oxidative stress paradigms.

Advanced Applications and Comparative Advantages

GS967 stands out over conventional agents, such as ranolazine, by offering both higher selectivity for late sodium current and reduced off-target effects, which is crucial for sensitive in vitro cardiac electrophysiology and for translational workflows in arrhythmia prevention research (article extension). In isolated rabbit hearts, GS967 effectively abolishes torsades de pointes (TdP) arrhythmias induced by toxins like ATX-II or E-4031, and reduces MAPD90 without impacting overall cardiac conduction time (APExBIO product data).

For ischemia-induced arrhythmia studies, GS967 prevents arrhythmic episodes triggered by clofilium or acute ischemic insult. Its use is also validated for decreasing Na⁺ and Ca²⁺ overload, a critical endpoint in ventricular myocyte sodium current inhibition and cardiac arrhythmia research. Compared to less selective blockers, GS967 preserves normal conduction and contractility, making it ideal for dissecting subtle pathophysiological mechanisms in both health and disease (practical troubleshooting guide).

GS967's solid, stable form and DMSO/ethanol solubility simplify storage and working solution preparation, removing a common technical barrier in high-throughput or long-term studies. As an APExBIO product, GS967 offers batch-to-batch consistency that enhances reproducibility across research groups.

Troubleshooting and Optimization Tips

• Compound precipitation: If cloudiness or precipitation appears after dilution, verify that solvent concentration remains above solubility thresholds and use ultrasonic agitation when dissolving in ethanol.
• Assay sensitivity: For patch-clamp and optical APD measurements, titrate GS967 from 0.05 to 0.5 μM to identify the minimal effective concentration for your specific model. Higher concentrations may suppress peak INa if not carefully controlled (protocol design guide).
• Solvent effects: Maintain final DMSO or ethanol concentration ≤0.1% v/v in physiological buffers to avoid cellular toxicity or non-specific electrophysiological effects.
• Long-term experiments: Prepare fresh working solutions for each experiment; avoid using solutions stored for more than a few hours at room temperature or 24 hours at 4°C.
• Control conditions: Always include vehicle controls and, where possible, positive controls (e.g., ranolazine) for benchmarking selectivity and efficacy.

For further workflow advice and troubleshooting, the practical troubleshooting guide details common pitfalls and laboratory solutions, while the advanced research guide offers integration strategies for complex models.

Outlook: Implications for Arrhythmia and Cardiac Aging Models

The growing elderly population and the high incidence of cardiac dysfunction underscore the urgent need for mechanistically-targeted interventions. The reference study's demonstration that late INa elevation, driven by Nav1.5 Ser571 phosphorylation, directly causes both delayed ventricular repolarization and diastolic dysfunction, highlights the translational value of late sodium current inhibition. By enabling selective, reproducible inhibition, GS967 empowers both academic and preclinical teams to model, dissect, and ultimately target age-related cardiac electrical and mechanical deficits (reference study).

Ongoing work with GS967 and related inhibitors will clarify the therapeutic window and downstream benefits in human-relevant models, while also refining our understanding of the molecular events underlying cardiac aging and arrhythmogenesis. For teams seeking robust, evidence-backed tools, APExBIO's GS967 stands out as a cornerstone for the next generation of cardiac arrhythmia research.